BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 15994145)

  • 1. Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma.
    Barbare JC; Bouché O; Bonnetain F; Raoul JL; Rougier P; Abergel A; Boige V; Denis B; Blanchi A; Pariente A; Milan C; Bedenne L
    J Clin Oncol; 2005 Jul; 23(19):4338-46. PubMed ID: 15994145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of advanced hepatocellular carcinoma with tamoxifen and the correlation with expression of hormone receptors: a prospective randomized study.
    Liu CL; Fan ST; Ng IO; Lo CM; Poon RT; Wong J
    Am J Gastroenterol; 2000 Jan; 95(1):218-22. PubMed ID: 10638587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Fédération Francophone de Cancérologie Digestive 9402).
    Doffoël M; Bonnetain F; Bouché O; Vetter D; Abergel A; Fratté S; Grangé JD; Stremsdoerfer N; Blanchi A; Bronowicki JP; Caroli-Bosc FX; Causse X; Masskouri F; Rougier P; Bedenne L;
    Eur J Cancer; 2008 Mar; 44(4):528-38. PubMed ID: 18242076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial.
    Chow PK; Tai BC; Tan CK; Machin D; Win KM; Johnson PJ; Soo KC;
    Hepatology; 2002 Nov; 36(5):1221-6. PubMed ID: 12395333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of leuprorelin and flutamide in male patients with hepatocellular carcinoma treated with tamoxifen.
    Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire
    Hepatology; 2004 Dec; 40(6):1361-9. PubMed ID: 15565568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support.
    Raoul JL; Guyader D; Bretagne JF; Duvauferrier R; Bourguet P; Bekhechi D; Deugnier YM; Gosselin M
    J Nucl Med; 1994 Nov; 35(11):1782-7. PubMed ID: 7525901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential prognostic benefits of radiotherapy as an initial treatment for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels.
    Nakazawa T; Adachi S; Kitano M; Isobe Y; Kokubu S; Hidaka H; Ono K; Okuwaki Y; Watanabe M; Shibuya A; Saigenji K
    Oncology; 2007; 73(1-2):90-7. PubMed ID: 18337620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma.
    Elba S; Giannuzzi V; Misciagna G; Manghisi OG
    Ital J Gastroenterol; 1994 Mar; 26(2):66-8. PubMed ID: 8032079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial.
    Manesis EK; Giannoulis G; Zoumboulis P; Vafiadou I; Hadziyannis SJ
    Hepatology; 1995 Jun; 21(6):1535-42. PubMed ID: 7768497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tamoxifen combined with octreotide or regular chemotherapeutic agents in treatment of primary liver cancer: a randomized controlled trial.
    Pan DY; Qiao JG; Chen JW; Huo YC; Zhou YK; Shi HA
    Hepatobiliary Pancreat Dis Int; 2003 May; 2(2):211-5. PubMed ID: 14599971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide.
    Rabe C; Pilz T; Allgaier HP; Halm U; Strasser C; Wettstein M; Sauerbruch T; Caselmann WH
    Z Gastroenterol; 2002 Jun; 40(6):395-400. PubMed ID: 12055662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment and prognostic factors in patients with hepatocellular carcinoma.
    Martins A; Cortez-Pinto H; Marques-Vidal P; Mendes N; Silva S; Fatela N; Glória H; Marinho R; Távora I; Ramalho F; de Moura MC
    Liver Int; 2006 Aug; 26(6):680-7. PubMed ID: 16842324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen does not improve overall survival in people with advanced-stage hepatocellular carcinoma.
    Chow PK
    Cancer Treat Rev; 2005 Oct; 31(6):491-5. PubMed ID: 16214294
    [No Abstract]   [Full Text] [Related]  

  • 14. Tamoxifen is not effective in good prognosis patients with hepatocellular carcinoma.
    Gallo C; De Maio E; Di Maio M; Signoriello G; Daniele B; Pignata S; Annunziata A; Perrone F;
    BMC Cancer; 2006 Jul; 6():196. PubMed ID: 16863588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres.
    Dancey JE; Shepherd FA; Paul K; Sniderman KW; Houle S; Gabrys J; Hendler AL; Goin JE
    J Nucl Med; 2000 Oct; 41(10):1673-81. PubMed ID: 11037997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis].
    Lim TY; Cheong JY; Cho SW; Sim SJ; Kim JS; Choi SJ; Choi JW; Kwon HC; Lee KM; Kim JK; Won JH; Yoo BM; Lee KJ; Hahm KB; Kim JH
    Korean J Hepatol; 2006 Mar; 12(1):65-73. PubMed ID: 16565607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High dose vitamin K3 infusion in advanced hepatocellular carcinoma.
    Sarin SK; Kumar M; Garg S; Hissar S; Pandey C; Sharma BC
    J Gastroenterol Hepatol; 2006 Sep; 21(9):1478-82. PubMed ID: 16911696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma.
    Yuen MF; Poon RT; Lai CL; Fan ST; Lo CM; Wong KW; Wong WM; Wong BC
    Hepatology; 2002 Sep; 36(3):687-91. PubMed ID: 12198662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.
    Barbare JC; Bouché O; Bonnetain F; Dahan L; Lombard-Bohas C; Faroux R; Raoul JL; Cattan S; Lemoine A; Blanc JF; Bronowicki JP; Zarski JP; Cazorla S; Gargot D; Thevenot T; Diaz E; Bastie A; Aparicio T; Bedenne L
    Eur J Cancer; 2009 Jul; 45(10):1788-97. PubMed ID: 19303768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
    Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.